Losartan 50 mg + Amlodipine 5 mg Fixed-Dose Combination Dosing
The recommended adult dose of the fixed-dose combination tablet containing losartan 50 mg and amlodipine 5 mg is one tablet once daily, which can be titrated to higher doses (losartan 100 mg/amlodipine 10 mg) if blood pressure remains uncontrolled after 2-4 weeks. 1
Standard Dosing Regimen
- Initial therapy: One tablet of losartan 50 mg/amlodipine 5 mg once daily, taken without regard to food 1, 2
- Titration schedule: If blood pressure target (<130/80 mmHg) is not achieved after 2-4 weeks, increase to losartan 100 mg/amlodipine 10 mg once daily 1
- Maximum dose: Losartan 100 mg/amlodipine 10 mg once daily 1, 2
When to Use This Combination
This fixed-dose combination is particularly recommended for patients with stage 2 hypertension (BP ≥140/90 mmHg or >20/10 mmHg above target), as initiating therapy with two first-line agents from different classes achieves faster blood pressure control and improves adherence. 1
- Fixed-dose combinations demonstrate greater blood pressure lowering than single agents and better long-term adherence 1
- The combination of an ARB (losartan) and a calcium channel blocker (amlodipine) provides complementary mechanisms: losartan blocks the renin-angiotensin system while amlodipine causes vasodilation 3
- Amlodipine prevents losartan-related compensatory increases in renin, while losartan reduces amlodipine-induced peripheral edema 3
Clinical Efficacy Evidence
- In stage 2 hypertensive patients, the losartan 50 mg/amlodipine 5 mg combination reduced systolic blood pressure by 36.5 mmHg at 6 weeks, significantly more than amlodipine 5 mg monotherapy (31.6 mmHg; p=0.0117) 4
- The combination was non-inferior to amlodipine 10 mg monotherapy in patients who failed amlodipine 5 mg alone, with comparable diastolic blood pressure reductions (8.9 vs 9.4 mmHg) 5
- Response rates (achieving BP <140/90 mmHg) with the combination reached 52.1% at 2 weeks versus 33.3% with monotherapy (p=0.0213) 4
Dosing Algorithm for Blood Pressure Control
Week 0-2:
Week 2-4:
- If BP remains ≥140/90 mmHg, titrate to losartan 100 mg/amlodipine 10 mg once daily 1
- Continue monitoring every 2-4 weeks until target achieved 1
Week 4-8:
- If BP still uncontrolled on maximum combination dose, add hydrochlorothiazide 12.5-25 mg daily as third agent 1, 4
- Target BP <130/80 mmHg should be achieved within 3 months 1
Individual Component Dosing Ranges
Losartan component:
- Usual dose range: 50-100 mg daily in 1 or 2 divided doses 1, 6
- Starting dose: 50 mg once daily 1, 7
- Target dose for hypertension: 100 mg daily 7, 6
- Maximum dose: 100 mg daily for hypertension (150 mg daily may be used in heart failure) 6, 2
Amlodipine component:
- Usual dose range: 2.5-10 mg once daily 1
- Starting dose: 5 mg once daily 1
- Maximum dose: 10 mg once daily 1
Critical Safety Monitoring
Within 1-2 weeks of initiation or dose changes:
- Check serum creatinine/eGFR and potassium levels, especially in patients with diabetes, chronic kidney disease, or those on potassium-sparing agents 6, 8
- Monitor for symptomatic hypotension or orthostatic changes, particularly in elderly patients 1
Ongoing monitoring:
- Blood pressure assessment every 2-4 weeks until target achieved, then at least annually 1
- Annual monitoring of electrolytes and renal function during maintenance therapy 6
Important Contraindications and Warnings
Never combine losartan with:
- ACE inhibitors (increases risk of hyperkalemia, syncope, and acute kidney injury without added benefit) 1, 6, 8
- Direct renin inhibitors like aliskiren (same risks as ACE inhibitor combination) 1, 6
Avoid in:
- Pregnancy (both losartan and amlodipine are contraindicated; serious fetal toxicity) 1, 6, 8
- Severe hepatic impairment (reduce losartan starting dose to 25 mg daily) 6
- Patients with history of angioedema with ARBs 1
Common Pitfalls to Avoid
- Underdosing: Less than 25% of patients are titrated to target doses in clinical practice; ensure uptitration to losartan 100 mg/amlodipine 10 mg if BP remains uncontrolled 6
- Premature addition of third agent: Allow 2-4 weeks at each dose level before escalating therapy 1, 4
- Ignoring adherence: Before escalating therapy, assess medication adherence as non-adherence is a common cause of apparent treatment failure 6
- Excessive caution in elderly: While monitoring is important, the combination is effective and generally well-tolerated in older adults when titrated appropriately 1
Special Populations
Elderly patients:
- Start with standard dose but monitor carefully for hypotension and orthostatic changes 1
- Titrate more gradually if history of hypotension or drug-associated side effects 1
Chronic kidney disease:
- Losartan is recommended for CKD with eGFR >30 mL/min/1.73 m² 6
- Monitor electrolytes and renal function closely within 1-2 weeks of initiation 6, 8
Diabetic patients: